NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the second tranche of €15 million (“Tranche B”) under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the “EIB) on December 28, 2022 (the “Finance Contract”). Tranche B is expected to be disbursed by the EIB by January 25, 2024. The Company plans to use the proceeds of Tranche B towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, and UCART123.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Mindpeak and DigitCells Forge Alliance to Advance AI-Powered Digital Pathology Workflows: A Paradigm Shift for Diagnostic Precision and Efficiency - April 21, 2025
- Hammond Power Solutions Announces First Quarter 2025 Financial Results Conference Call and Webcast Notification - April 21, 2025
- ThriftBooks® Launches ThriftBooks BuyBack Program Features for Bulk Booksellers - April 21, 2025
